Latest Financial Impact News

Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.

Bega Cheese Limited has delivered a robust FY2026 with a $54.8 million statutory profit, a 6.7% revenue increase, and a raised final dividend of 7.5 cents per share. The company is advancing its strategic growth plans focused on high-protein products, international expansion, and sustainability initiatives.

Brambles Limited posted a 6% rise in sales revenue to US$7.04 billion for FY26, navigating US repair bottlenecks with decisive investments and reaffirming growth targets for FY27 and beyond.

Australian Finance Group (ASX:AFG) reported a 39% jump in FY26 net profit after tax to AUD 48.5 million, driven by growth across its broker network and lending book, alongside its first mandatory climate disclosures.

Medibank Private Limited reported a 27.5% jump in net profit after tax to $638.7 million for FY26, driven by steady health insurance growth and a 31.3% surge in its Medibank Health segment. The company declared a fully franked final dividend of 10.9 cents per share and updated its Net Zero emissions strategy.

Southern Cross Electrical Engineering’s FY26 underlying profits surged despite a $46.1 million WestConnex arbitration settlement dragging statutory net profit sharply lower. The group declared a record dividend and raised FY27 EBITDA guidance by 30%.

Judo Bank posted a 34% rise in profit before tax to $168 million for FY26, driven by robust loan book growth and operating leverage, despite increased impairment expenses.

CSL Limited’s FY2026 results reveal modest revenue growth offset by a multibillion-dollar statutory loss driven by restructuring and impairments, alongside a maintained dividend and a strategic focus on sustainable growth.

Scott Technology has locked in NZ$20 million worth of new Materials Handling & Logistics contracts across North America and Europe, reinforcing its Destination 2030 growth strategy and building on strong FY26 momentum.

CVC Limited has decided to let its option to purchase the Liverpool project lapse, triggering a $13 million write-down but avoiding a major cash outflow. The vendor will refund approximately $46 million over coming months, cushioning the financial impact.

Dimerix has secured full sponsorship of the US Investigational New Drug application for its Phase 2-ready kidney drug DMX-652, setting the stage for a clinical trial targeting acute kidney injury in late 2026.

Audinate Group Limited reported a 15% revenue increase driven by its expanding Dante ecosystem and Iris acquisition, but underlying EBITDA losses widened amid restructuring and investment costs.